LL-37 side effects and risks

Reported side effects

• Redness, swelling or irritation around ulcers: Pooled across all arms: ulcer redness 42.6%, swelling 39.2%; nearby skin redness 54.1%. No consistent excess versus placebo., mild. Assess local changes at each dressing change. (source)
• Adverse events during topical treatment: Any event: 20/48 at 0.5 mg/mL, 24/49 at 1.6 mg/mL, 20/51 placebo. These are not all drug caused., moderate. Review new symptoms; topical trial results do not describe injected-product safety. (source)
• Serious events during topical study: 11/148, 7.4%, across all arms. None was judged related to study drug; no deaths., serious. Seek urgent assessment of serious symptoms. (source)
• Irritant dermatitis in foot-ulcer trial: 1/13 active participants; attributed to excess wound fluid rather than LL 37 itself., mild. Have wound care reassessed. (source)
• Immune reactions or inflammatory flares: FDA flags immune reaction risk; systemic incidence is unknown. Laboratory work links LL 37 to autoimmune signaling., serious. New rash, swelling or systemic worsening needs assessment. (source)
• Symptoms reported after community use: One user described persistent spinal spasms and dry hair after a 4 week course; causation was not verified., moderate. Obtain assessment rather than using another untested peptide to reverse symptoms. (source)

Stop and get help if

• Breathing trouble, tongue or throat swelling, or fainting: Stop and get emergency care immediately.
• Spreading hot redness, increasing wound pain or fever: Seek urgent assessment for wound infection; LL-37 is not a proven substitute for infection care.
• New severe symptoms after an injection or rapidly worsening skin disease: Stop and seek prompt medical review; do not assume this is a helpful immune or detox response.

Who should avoid it

• pregnant: Precautionary block. Pregnancy was excluded from human trials; fetal safety is unknown.
• breastfeeding: Precautionary block. Breastfeeding was excluded; infant exposure and effects are unknown.
• tryingToConceive: Sperm-damaging effects occurred in lab and mouse work. Human reproductive risk from dosing is unknown.
• under18: No pediatric dosing or safety regimen established; human dosing studies were in adults.
• activeCancer: Precautionary block outside oncology research. FDA cites tumor-promoting findings in some tissues; LL-37 also promotes vessel growth.
• cancerHistory: Discuss prior cancer with oncology. Effects depend on the tissue and are not established by the three-person melanoma results.
• autoimmuneDisease: LL-37 can drive self-DNA immune signaling. Active autoimmune disease was excluded from the melanoma study.
• immunosuppressed: The melanoma trial excluded immune deficiency and systemic steroids; infection and immune effects remain uncertain.
• kidneyDisease: Human systemic clearance and kidney dose adjustments are unknown; the melanoma trial imposed kidney-function limits.
• liverDisease: No established liver dose adjustment; the melanoma trial required acceptable bilirubin, ALT and AST.
• other: Avoid re-exposure after a serious allergy to LL-37 or its formulation.
• testedAthlete: S0 prohibits unapproved pharmacological substances at all times. Verify status with the relevant anti-doping body.

Interactions

• Systemic steroids and other immunosuppressants: Immune effects may conflict. This is a precaution, not a proven interaction; systemic steroids were excluded from the melanoma trial.
• Other immune-active peptide stacks: No human combination trial found. Duplicate LL-37 exposure and multi-peptide immune effects have no established safety limits.

Product quality risks

• FDA flags immune reactions, peptide impurities and difficulty characterizing the active ingredient.
• Unregulated peptides may contain the wrong amount or ingredient, microbes or endotoxins; these risks lack LL-37-specific market rates.
• Trial material underwent content, impurity and identity testing. A research-vial label does not establish equivalent quality.